When Will There Be a COVID-19 Vaccine for Kids?

By Elaine K. Howley Over the last year, a heroic effort has brought about multiple safe and effective vaccines that offer excellent protection against COVID-19. States and the federal government have made considerable progress rolling out these vaccines (…)

How COVID-19 has fundamentally changed clinical research in global health

By: Jay J HParkMSc, RobinMoggPhD, Gerald ESmithMSc, EtheldredaNakimuli-MpunguPhD, FyezahJehanMBBS, Craig RRaynerPharmD, JeanineCondoPhD, Eric HDecloedtPhD, ProfJean BNachegaPhD, GilmarReisPhD, ProfEdward, JMillsFRCP COVID-19 has had negative repercussions on the entire global population. Despite there being a common goal that should have unified resources and efforts, there have been an overwhelmingly large number of clinical trials that have been … Continued

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou Hemorrhagic cystitis (HC) caused by viral infections such as BK virus, cytomegalovirus, and/or adenovirus after allogeneic hematopoietic stem cell transplantation (allo-HCT) causes morbidity and mortality, affects quality of life, and poses a substantial burden to the health care system. At … Continued

Modelling and simulation facilitates drug repurposing to counter Covid-19

By Dr Craig R. Rayner, FRCP Edin, PharmD, MBA, President, Integrated Drug Development at Certara Right at the start of the Covid-19 pandemic, medical researchers began questioning whether there were any existing, on-market drugs that might prove effective against SARS-CoV-2. They wanted to offer healthcare professionals and patients some known therapeutic options while researchers quickly began developing … Continued

Legislators: Bring all stakeholders to the table to lower drug costs

BY ROMAN CASCIANO, OPINION CONTRIBUTOR — 03/29/21 05:30 PM EDT No one is happy with the price of drugs nor how we pay for them: not patients, not the lawmakers who represent them, not physicians, not insurance payers and not drug developers. We are at a point where all stakeholders are fed up, and there’s (…)


By: Sumeet Bakshi, Vice President, Real World Data Solutions, Certara’s Evidence, Value & Access groupRichard Tao, Associate Principal Regulatory Writer and Submission Leads Member, Synchrogenix, Certara’s regulatory science company Employing real-world evidence allows for the study of many aspects of diseases, such as natural history, patient populations, and outcomes, under everyday conditions. Therefore, real-world evidence has many … Continued

1 of 7
Back to top
Powered by Translations.com GlobalLink OneLink Software